M.A. Argiriadi

Abbott (United Kingdom)

Papers

1

Total Citations

11

H-Index

1

About

M.A. Argiriadi is a structural biologist whose work bridges the gap between protein engineering and rational drug design. Her research centers on kinase biology, particularly the structural characterization of MAPKAP kinase 2 (MK2), a key mediator in inflammatory signaling pathways. Argiriadi’s major contribution lies in demonstrating how targeted mutagenesis can stabilize flexible protein regions for X-ray crystallography, enabling structure-based drug design for challenging therapeutic targets. Her seminal paper, "Rational mutagenesis to support structure-based drug design: MAPKAP kinase 2 as a case study" (2009), has garnered 11 citations, establishing a methodological framework that has been adopted by researchers seeking to solve structures of dynamic kinases. This work exemplifies her ability to combine molecular biology with structural insights, providing a blueprint for overcoming crystallization bottlenecks in drug discovery. Argiriadi’s achievements highlight the critical role of protein engineering in translating structural data into actionable drug design strategies, making her a notable figure in the field of kinase-targeted therapeutics.

Research Focus

Key Achievements

1
H-Index
1
Papers
11
Total Citations
11
Avg Citations/Paper
🏆 Most Cited Paper
Rational mutagenesis to support structure-based drug design: MAPKAP kinase 2 as a case study
11 citations · 2009
📈 Most Prolific Year: 2009 (1 Papers)
🤝 Key Collaborators: 17
🏛 Institutions: Abbott (United Kingdom)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago